Home›Oncology› Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancerTranscriptomic Signatures May Help Predict Pancreatic Cancer Outcomes
Cancer lettersPublished October 10, 2026Study authors: Zhao Shulin, Nicolle Remy, Taieb Julien, Dahan Laetitia, Abdallah Raef, Bouché Olivier, Desrame Jérô…PubMed ↗DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that the immune classical subtype is associated with superior PFS and OS in metastatic pancreatic cancer.
This retrospective pooled analysis of phase 2 trials evaluates the prognostic and predictive utility of transcriptomic signatures and GemPred status in patients with metastatic pancreatic cancer. The study analyzed 178 patients to determine how molecular subtypes and specific components influence outcomes for first-line regimens including FOLFIRINOX, GemNab, FuNab, and FOLFIRI3.
Key findings indicate that the immune classical subtype is associated with superior outcomes, with a median progression-free survival (PFS) of 9.03 months compared to basal-like and stroma-activated subtypes (p = 0.015). Similarly, the immune classical subtype showed a median overall survival (OS) of 11.27 months (p = 0.010). A higher classical component correlated with improved OS (HR = 0.737, p = 0.005), while inactive stroma predicted better PFS (HR = 0.66, p = 0.003) and better OS (HR = 0.697, p = 0.013).
In patients who were GemPred-negative, FOLFIRINOX was associated with higher objective response rates (46.9% vs. 19.1%, p = 0.046), longer PFS (8.2 vs. 2.3 months, HR = 2.28, p = 0.008), and longer OS (11.6 vs. 5.0 months, HR = 2.04, p = 0.021) compared to GemNab. The authors note that while transcriptomic signatures retain prognostic utility, GemPred is currently a hypothesis-generating predictive signal for OS in GemPred-negative patients. Prospective validation is required before these markers can be implemented in clinical practice.
How this fits prior evidence
This analysis addresses a gap in the understanding of molecular subtypes in pancreatic cancer. While prior evidence established that Gemcitabine plus nab-paclitaxel demonstrates superior OS and PFS compared to modified FOLFIRINOX in unresectable cases, this study identifies specific transcriptomic signatures, such as the immune classical subtype, that correlate with superior outcomes. It also identifies GemPred as a potential predictive signal for FOLFIRINOX selection in specific subsets.
Researchers analyzed data from 178 patients with metastatic pancreatic cancer to see if certain molecular markers, called transcriptomic signatures, could predict how well patients would respond to first-line treatments. The study looked at several common chemotherapy combinations, including FOLFIRINOX and GemNab.
The results showed that patients with a specific signature called the immune classical subtype had longer median progression-free survival and overall survival compared to other groups. Additionally, the study found that patients with a specific marker called GemPred-negative showed better survival outcomes when treated with the FOLFIRINOX regimen compared to GemNab.
It is important to note that this was a retrospective analysis of phase 2 trials, which means the results are not yet ready for everyday clinical use. The researchers noted that while some markers showed promise, they are currently considered hypothesis-generating tools. More forward-looking studies are needed to confirm these findings before they can be used to guide standard medical decisions.
What this means for you:
Specific genetic markers may help predict how pancreatic cancer patients respond to certain chemotherapy treatments.
Common questions
What did the study find about different types of pancreatic cancer?
The study found that patients with the immune classical subtype had a median progression-free survival of 9.03 months and an overall survival of 11.27 months. These results were significantly better than those seen in the basal-like and stroma-activated groups.
How did the FOLFIRINOX treatment compare to GemNab?
In patients who were GemPred-negative, those treated with FOLFIRINOX showed a higher objective response rate of 46.9% compared to 19.1% for GemNab. These patients also had longer progression-free survival and overall survival when receiving FOLFIRINOX.
Can these findings be used to choose a treatment right now?
Not yet. Because this was a retrospective analysis of phase 2 trials, the findings are currently considered hypothesis-generating. The researchers stated that prospective validation is still needed before these markers can be used in routine clinical practice.
To evaluate the clinical applicability of previously established transcriptomic signatures (molecular subtypes, components and GemPred status) in metastatic pancreatic cancer, we conducted a retrospective pooled analysis of 178 patients from three phase 2 trials (PRODIGE35/37, AFUGEM; 2013-2016) testing first-line regimens (FOLFIRINOX, GemNab, FuNab, FOLFIRI3). RNA sequencing was performed on primary/metastatic tumors across French centers, with blinded assessment of subtypes (immune classical, pure basal-like, stroma-activated), quantitative components, and GemPred status. Primary endpoint: progression-free survival (PFS). Immune classical subtype showed superior median PFS (9.03 months) and OS (11.27 months) versus basal-like and stroma-activated subtypes (PFS: p = 0.015; OS: p = 0.010). Higher classical component correlated with improved OS (HR = 0.737, p = 0.005) but not PFS (HR = 0.90, p = 0.339). Inactive stroma predicted better PFS (HR = 0.66, p = 0.003) and OS (HR = 0.697, p = 0.013). GemPred-negative patients treated with FOLFIRINOX versus GemNab had higher ORR (46.9% vs. 19.1%, p = 0.046), longer PFS (8.2 vs. 2.3 months; HR = 2.28, p = 0.008), and OS (11.6 vs. 5.0 months; HR = 2.04, p = 0.021). No differences occurred in GemPred-positive patients. In a formal treatment-by-GemPred interaction analysis (FOLFIRINOX vs. GemNab), the interaction was significant for OS (adjusted p-interaction = 0.050) but not for PFS (adjusted p-interaction = 0.51). Transcriptomic signatures retain prognostic and predictive utility in metastatic pancreatic cancer, with GemPred representing a hypothesis-generating predictive signal for OS (e.g., a FOLFIRINOX OS benefit in GemPred-negative). Prospective validation is warranted for clinical implementation.
